Maine Revised Statutes Title 32 Sec. 13841 – Authority
Current as of: 2023 | Check for updates
|
Other versions
1. Engage in collaborative drug therapy management. A pharmacist licensed in this State who meets the qualifications and requirements of section 13842 and rules adopted by the board may engage in collaborative drug therapy management pursuant to a collaborative practice agreement with a practitioner.
[PL 2013, c. 308, §4 (NEW).]
Terms Used In Maine Revised Statutes Title 32 Sec. 13841
- Board: means the Maine Board of Pharmacy. See Maine Revised Statutes Title 32 Sec. 13702-A
- Collaborative drug therapy management: includes collecting and reviewing patient histories; obtaining and checking vital signs, including pulse, temperature, blood pressure and respiration; and, under the supervision of, or in direct consultation with, a practitioner, ordering and evaluating the results of laboratory tests directly related to drug therapy when performed in accordance with approved protocols applicable to the practice setting and when the evaluation does not include a diagnostic component. See Maine Revised Statutes Title 32 Sec. 13702-A
- Collaborative practice agreement: means a written and signed agreement between one or more pharmacists with training and experience relevant to the scope of the collaborative practice and a practitioner that supervises or provides direct consultation to the pharmacist or pharmacists engaging in collaborative drug therapy management that:
A. See Maine Revised Statutes Title 32 Sec. 13702-ADrug: means :
A. See Maine Revised Statutes Title 32 Sec. 13702-APharmacist: means an individual provider of health care services licensed by this State to engage in the practice of pharmacy. See Maine Revised Statutes Title 32 Sec. 13702-A Practitioner: means an individual who is licensed, registered or otherwise authorized in the appropriate jurisdiction to prescribe and administer drugs in the course of professional practice. See Maine Revised Statutes Title 32 Sec. 13702-A
2. Scope of authority. A pharmacist engaging in collaborative drug therapy management pursuant to subsection 1 is entitled to adequate access to a patient’s history, disease status, drug therapy and laboratory and procedure results and may:
A. Collect and review a patient’s history; [PL 2013, c. 308, §4 (NEW).]
B. Obtain and check vital signs; [PL 2013, c. 308, §4 (NEW).]
C. Order and evaluate the results of laboratory tests directly related to drug therapy under the supervision of, or in direct consultation with, a practitioner and in accordance with approved protocols applicable to the practice setting and when the evaluation does not include a diagnostic component; and [PL 2013, c. 308, §4 (NEW).]
D. Initiate, administer, monitor, modify and discontinue drug therapy for a particular patient pursuant to the collaborative practice agreement with a practitioner who is treating the patient, as long as the action is reported to the practitioner in a timely manner as determined by rules adopted pursuant to section 13846. [PL 2021, c. 271, §5 (AMD).]
[PL 2021, c. 271, §5 (AMD).]
SECTION HISTORY
PL 2013, c. 308, §4 (NEW). PL 2021, c. 271, §5 (AMD).